1998 …2024

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 18 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Research Output

    Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

    Schafer, E. S., Rau, R. E., Berg, S. L., Liu, X., Minard, C. G., Bishop, A. J. R., Romero, J. C., Hicks, M. J., Nelson, M. D., Voss, S., Reid, J. M., Fox, E., Weigel, B. J. & Blaney, S. M., Feb 1 2020, In : Pediatric Blood and Cancer. 67, 2, e28073.

    Research output: Contribution to journalArticle

  • A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: Children's Oncology Group Phase I and pilot Consortium (ADVL0921)

    Mosse, Y. P., Fox, E., Teachey, D. T., Reid, J. M., Safgren, S. L., Carol, H., Lock, R. B., Houghton, P. J., Smith, M. A., Hall, D., Barkauskas, D. A., Krailo, M., Voss, S. D., Berg, S. L., Blaney, S. M. & Weigel, B. J., Jun 1 2019, In : Clinical Cancer Research. 25, 11, p. 3229-3238 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 5 Scopus citations

    Identification of aggressive Gardner syndrome phenotype associated with a de novo APC variant, c.4666dup

    Kiessling, P., Dowling, E., Huang, Y., Ho, M. L., Balakrishnan, K., Weigel, B. J., Edward Highsmith, W., Niu, Z. & Schimmenti, L. A., Jan 1 2019, In : Cold Spring Harbor Molecular Case Studies. 5, 2, a003640.

    Research output: Contribution to journalArticle

    Open Access
  • Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group

    Kopp, L. M., Malempati, S., Krailo, M., Gao, Y., Buxton, A., Weigel, B. J., Hawthorne, T., Crowley, E., Moscow, J. A., Reid, J. M., Villalobos, V., Randall, R. L., Gorlick, R. & Janeway, K. A., Nov 2019, In : European Journal of Cancer. 121, p. 177-183 7 p.

    Research output: Contribution to journalArticle

  • The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group

    Malempati, S., Weigel, B. J., Chi, Y. Y., Tian, J., Anderson, J. R., Parham, D. M., Teot, L. A., Rodeberg, D. A., Yock, T. I., Shulkin, B. L., Spunt, S. L., Meyer, W. H. & Hawkins, D. S., Jan 15 2019, In : Cancer. 125, 2, p. 290-297 8 p.

    Research output: Contribution to journalArticle

    Open Access
  • 6 Scopus citations